


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (1):



formula (1)

wherein:

Z is selected from $-\text{CONR}^{15}\text{OH}$ and $-\text{N}(\text{OH})\text{CHO}$;

R^{15} is hydrogen or $\text{C}_{1-3}\text{alkyl}$;

R^1 is hydrogen or a group selected from $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{3-7}\text{cycloalkyl}$, $\text{C}_{5-7}\text{cycloalkenyl}$, aryl and heteroaryl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{2-4}\text{alkenyl}$, $\text{C}_{2-4}\text{alkynyl}$, $\text{C}_{3-6}\text{cycloalkyl}$ (optionally substituted by one or more R^{17}), aryl (optionally substituted by one or more R^{17}), heteroaryl (optionally substituted by one or more R^{17}), heterocyclyl, $\text{C}_{1-4}\text{alkoxycarbonyl}$, $-\text{OR}^5$, $-\text{SR}^2$, $-\text{SOR}^2$, $-\text{SO}_2\text{R}^2$, $-\text{COR}^2$, $-\text{CO}_2\text{R}^5$, $-\text{CONR}^5\text{R}^6$, $-\text{NR}^{16}\text{COR}^5$, $-\text{SO}_2\text{NR}^5\text{R}^6$ and $-\text{NR}^{16}\text{SO}_2\text{R}^2$;

R^{16} is hydrogen or $\text{C}_{1-3}\text{alkyl}$;

R^{17} is selected from halo, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$ and $\text{C}_{1-6}\text{alkoxy}$;

R^2 is group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl where the group is optionally substituted by one or more halo;

R^5 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{5-7} cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryl C_{1-4} alkyl and heteroaryl C_{1-4} alkyl where the group is optionally substituted by one or more halo;

R^6 is hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

or R^5 and R^6 together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

R^8 is hydrogen or a group selected from C_{1-6} alkyl, C_{3-7} cycloalkyl and C_{5-7} cycloalkenyl where the group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy and C_{1-4} alkyl;

R^3 and R^4 are both hydrogen;

n is 0 or 1;

m is 0 or 1;

D is hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl or fluoro;

X is O, S, SO or SO_2 ;

B is monocyclic aryl or heteroaryl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C_{1-4} alkyl (optionally substituted by R^{13}), C_{2-4} alkenyl (optionally substituted by R^{13}), C_{2-4} alkynyl (optionally substituted by R^{13}), C_{3-6} cycloalkyl (optionally substituted by R^{13}), C_{3-6} cycloalkenyl (optionally substituted by R^{13}), phenyl (optionally substituted by halo or C_{1-4} alkyl), heteroaryl (optionally substituted by halo or C_{1-4} alkyl), heterocyclyl (optionally substituted by halo or C_{1-4} alkyl), C_{1-4} alkylthio, C_{3-6} cycloalkylthio, $-SOR^{13}$, $-SO_2R^{13}$, $-SO_2NHR^{13}$, $-SO_2NR^{13}R^{14}$, $-NHSO_2R^{13}$, $-NR^{13}SO_2R^{14}$, $-NHCONHR^{13}$, $-NHCONHR^{13}R^{14}$, $-OR^{13}$, cyano, $-CONR^{13}R^{14}$, $-NHCOR^{13}$, $-CO^2R^{13}$ and $-CH_2CO_2R^{13}$;

or B is bicyclic aryl or heteroaryl where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, C₁₋₄alkyl (optionally substituted by R¹³), C₂₋₄alkenyl (optionally substituted by R¹³), C₂₋₄alkynyl (optionally substituted by R¹³), C₃₋₆cycloalkyl (optionally substituted by R¹³), C₃₋₆cycloalkenyl (optionally substituted by R¹³), C₁₋₄alkylthio, C₃₋₆cycloalkylthio, -SOR¹³, -SO₂R¹³, -SO₂NHR¹³, -SO₂NR¹³R¹⁴, -NSO₂R¹³, -NR¹³SO₂R¹⁴, -NHCONHR¹³, -NHCONHR¹³R¹⁴, -OR¹³, cyano, -CONR¹³R¹⁴ and -NHCOR¹³;

R¹³ and R¹⁴ are independently hydrogen, C₁₋₆alkyl or C₃₋₆cycloalkyl; or R¹³ and R¹⁴ together with the nitrogen to which they are attached form a heterocyclic 4 to 7-membered ring.

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 wherein B is phenyl or pyridyl where each is substituted in an ortho position by, and is optionally further substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C₁₋₄alkoxy, C₁₋₄alkyl, nitro, aryl, heteroaryl, heterocyclyl, N-(C₁₋₄alkyl)carbamoyl and N,N-(C₁₋₄alkyl)₂carbamoyl; or B is naphthyl, quinolinyl, thieno[2,3-*d*]pyrimidinyl or thieno[3,2-*d*]pyrimidinyl each being optionally substituted by one or more groups independently selected from halo, trifluoromethyl, cyano, C₁₋₄alkoxy, C₁₋₄alkyl, aryl, heteroaryl, heterocyclyl and nitro.

3. (Currently amended) A compound according to claim 1-~~or 2~~ wherein R¹ is a group selected from C₁₋₆alkyl, C₃₋₆cycloalkyl, aryl, heteroaryl and C₁₋₆alkyl substituted by aryl or heteroaryl wherein any R¹ group is optionally substituted by one or more substituents independently selected from halo, C₁₋₄alkoxy, C₁₋₄alkyl and C₃₋₆cycloalkyl.

4. (Currently amended) A compound according to ~~any one of claims 1 to 3~~ claim 1 wherein X is O.

5. (Cancelled)

6. (Currently amended) A method, the method comprising treating a disease condition mediated by one or more metalloproteinase enzymes by administering to a warm-blooded animal
~~The use of a compound according to any one of claims 1 to 4 claim 1 in the manufacture of a medicament in the treatment of a disease condition mediated by one or more metalloproteinase enzymes.~~


7. (Currently amended) A method, the method comprising treating a disease condition mediated by TNF α , by administering to a warm-blooded animal
~~The use of a compound according to any one of claims 1 to 4 claim 1 in the manufacture of a medicament in the treatment of a disease condition mediated TNF α .~~

8. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 4~~ claim 1; and a pharmaceutically-acceptable diluent or carrier.

9. (Original) A method of treating autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound according to claim 1.


10. (Original) A process for preparing a compound of formula (1) according to claim 1 comprising, when Z is $-N(OH)CHO$, the step of:

a) converting a hydroxylamine of formula (2) into a compound of formula (1);



or when Z is $-\text{CONR}^{15}\text{OH}$, the step of:

b) converting an acid of formula (14) into a compound of formula (1);



and thereafter if necessary:

- i) converting a compound of formula (1) into another compound of formula (1);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.